EAGAN, MINNESOTA – November 3, 2003 – Biopolymer Engineering, Inc., a privately held biotechnology company, announced today that it has obtained $1.5 million in additional loan financing from private investors. The funds will be invested in the continued development of the company’s pharmaceutical and commercial businesses, which leverage a common technology platform of complex carbohydrates that enhance immune health.

Specifically, Biopolymer Engineering will use part of the new capital to fund human clinical research for its pharmaceutical compounds. The studies will test the efficacy of the compounds in working with other therapies to treat cancer and infectious disease. The funding will also be used to increase sales in the company’s commercial businesses, which include the marketing of immune-enhancing compounds as specialty ingredients for use in nutritional supplements, functional foods, cosmetics and animal feed and nutrition.

“The expanded capital will help us advance our technology for pharmaceutical use, as well as expand the growing sales of our commercial products,” said Richard G. Mueller, president and chief executive officer of Biopolymer Engineering.

The company continues to raise additional capital for the execution of its business plan, which is primarily focused on the development and license of its technologies to major biotech and pharmaceutical companies. Biopolymer Engineering is currently in the final phase of an equity offering at $13.50 per common share.

Biopolymer Engineering, Inc. is a privately held biotechnology company focused on developing carbohydrate technologies to improve immune health. Founded in 1997 and based in Eagan, Minnesota, the company has more than 40 U.S. patents and patents pending, with additional filings in more than 30 countries. Website: www.biopolymer.com.